Moses Laman is a Principle Research Fellow and the current Head of the Vector Borne Diseases Unit at the Papua New Guinea Institute of Medical Research. He is a Young Affiliate of the Third World Academy of Science, a general paediatrician and an adjunct senior research fellow at the School of Medicine and Pharmacology, University of Western Australia. Over the past 12 years, he has led multiple field-based and health facility-based studies of malaria and other diseases of public health importance in developing countries. Moses collaborates widely with many international research groups and his in-depth understanding of the Melanesian culture, values, perspectives and relationships continue to be instrumental to the success of these studies.Related Projects
- Access and adherence to malaria interventions
- Geographical information systems and spatial decision support systems.
- Identifying “hot spots” and “hot pops” with serological surveillance and operational research of high sensitivity tests
- Identifying better treatments for uncomplicated malaria
- Molecular surveillance of malaria parasites to inform on local intervention strategies
- Pregnant women and malaria surveillance
Related Publications
- A molecular barcode and web-based data analysis tool to identify imported Plasmodium vivax malaria
- Acquisition of antibodies against endothelial protein C receptor-binding domains of Plasmodium falciparum erythrocyte membrane protein 1 in children with severe malaria
- Antibody targets on the surface of Plasmodium falciparum-infected erythrocytes that are associated with immunity to severe malaria in young children
- Antibody to Plasmodium falciparum variant surface antigens, var gene transcription and ABO blood group in children with severe or uncomplicated malaria
- Asia-Pacific ICEMR: Understanding Malaria Transmission to Accelerate Malaria Elimination in the Asia Pacific Region
- Asia-Pacific International Center of Excellence in Malaria Research: Maximizing Impact on Malaria Control Policy and Public Health in Cambodia and Papua New Guinea
- Global diversity and balancing selection of 23 leading Plasmodium falciparum candidate vaccine antigens
- Identifying and combating the impacts of COVID-19 on malaria
- Short-course, high-dose primaquine regimens for the treatment of liver-stage vivax malaria in children
- The association of intraleucocytic malaria pigment and disease severity in Papua New Guinean children with severe P. falciparum malaria
- The efficacy of dihydroartemisininpiperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis
- The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network
- Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment
- Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment
- Variability in white blood cell count during uncomplicated malaria and implications for parasite density estimation: a WorldWide Antimalarial Resistance Network individual patient data meta-analysis